Skip to content
CancerIndex

Publication

PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.

Authors not recorded

Clin Cancer Res2017PMID 28424201PMC5559326stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (9)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 9

Curated evidence

Evidence citing this paper (6)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
28424201
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–6 of 6 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
PIK3CA F930S1
CetuximabMalignant Colorectal NeoplasmCURATED_BROADERPredictiveCSupports Resistance4accepted
EID10032

A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. One patient had the PIK3… (full text at CIViC)

PMID 28424201 · Xu et al., 2017 · Open in CIViC

civic
PIK3CA K944N1
CetuximabMalignant Colorectal NeoplasmCURATED_BROADERPredictiveCSupports Resistance4accepted
EID10031

A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. Three patients had the P… (full text at CIViC)

PMID 28424201 · Xu et al., 2017 · Open in CIViC

civic
PIK3CA K966E1
CetuximabMalignant Colorectal NeoplasmCURATED_BROADERPredictiveCSupports Resistance4accepted
EID10034

A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. One patient had the PIK3… (full text at CIViC)

PMID 28424201 · Xu et al., 2017 · Open in CIViC

civic
PIK3CA L938*1
CetuximabMalignant Colorectal NeoplasmCURATED_BROADERPredictiveCDoes Not Support Resistance3accepted
EID10035

A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed. One patient was found to have the PIK3CA p.L938* mutation in FFPE tumour tissue prior to … (full text at CIViC)

PMID 28424201 · Xu et al., 2017 · Open in CIViC

civic
PIK3CA V955G1
CetuximabMalignant Colorectal NeoplasmCURATED_BROADERPredictiveCSupports Resistance4accepted
EID10033

A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. One patient had the PIK3… (full text at CIViC)

PMID 28424201 · Xu et al., 2017 · Open in CIViC

civic
PIK3CA V955I1
CetuximabMalignant Colorectal NeoplasmCURATED_BROADERPredictiveCSupports Resistance4accepted
EID8063

Among 32 colorectal cancer patients with acquired resistance (PFS > 12 weeks) to cetuximab, one was determined to have V955I mutation. V995I allelic fractions low at start of treatment but increased i… (full text at CIViC)

PMID 28424201 · Xu et al., 2017 · Open in CIViC

civic